Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs
In this week’s news, Advent International has agreed to sell the Czech generic drugmaker Zentiva to private equity firm G...
Impressions : 1220
Pfizer’s Covid-19 pill retains 89 percent efficacy, works on Omicron; CSL buys Vifor for US$ 11.7 billion
In
this week’s Phispers, we bring you news on several M&As and tie-ups along with updates on Covid-19 medications an...
Impressions : 1662
Big pharma slash prices for China’s insurance scheme; plan major investments in gene therapy
This week, Phispers brings you news on 11 large multinational drugmakers, including Pfizer and Novartis, that have set aside US...
Impressions : 2185
Insys founder Kapoor convicted in opioid scandal; FDA rules changing due to new technologies
This week, Phispers brings you news about John Kapoor, the founder of Insys who was found guilty of engaging in a bribery schem...
Impressions : 3744
Top drugs and pharmaceutical companies of 2018 by revenues
The drug pricing debate continued to dominate news headlines in 2018, and many companies were in the news for lowering drug pri...
Impressions : 35127
FDA approves first flu drug in 20 years; Trump proposes global index to check drug price rise
This week, Phispers brings you news on US President Donald Trump’s new payment model, proposed ahead of the midterm polls...
Impressions : 6518
High-level exit at Dr. Reddy’s; Drug stockpiling starts as firms face ‘no-deal Brexit’ blues
With Britain preparing for a ‘no-deal Brexit’, Phispers this week looks at how pharmaceutical companies are ex...
Impressions : 3404
Dr. Reddy’s restrained from rolling out generic opioid addiction drug; FDA rejects Mylan’s Advair generic
This week in Phispers, there is news on Indian drugmaker Dr. Reddy’s, which got an FDA nod for the generic version of Ind...
Impressions : 4227
PhRMA publishes list of US cancer drug pipeline; Biocon-Mylan’s Neulasta biosim bags FDA nod
This week in Phispers, Biocon–Mylan scored a big win by getting the FDA nod for its biosimilar to Amgen’s Neulasta....
Impressions : 2480
AstraZeneca’s shareholders rebel over CEO pay; FDA lashes out at IQVIA over erroneous data
Soon after
US President Donald Trump revealed his new drug pricing plan, the FDA took a
tough stand by releasing a list of dr...
Impressions : 5188
Takeda to buy Shire for US$ 65 billion; Fresenius dumps Akorn over data-integrity concerns
PharmaCompass has maintained that 2018 would be the year of M&As. This week’s Phispers only reaffirms our conviction ...
Impressions : 3503
Novartis buys gene therapy for US$ 8.7 billion; France to target healthcare for its AI strategy
This week in
Phispers, we have some good and bad news on Swiss drugmaker, Novartis. While it acquired gene-therapy company AveX...
Impressions : 4397
Apotex’s founder was murdered, its president resigns; Daiichi to recover $551 million from Ranbaxy promoters
This week in Phispers, we bring you news on the Singh brothers, the former promoters of Ranbaxy, who lost a case in the Delhi h...
Impressions : 5914
A week of US$ 20 billion deals; Teva’s asthma drug fails to deliver; to layoff 200 in US
The first month of 2018 ended with a bang, with several big ticket M&A deals and bids. While Sanofi bought Bioverativ for U...
Impressions : 4242
Novartis considering a sale of Sandoz’s oral solids business; Sanofi’s dengue vaccine found to make disease worse
This week, Phispers brings you news on the biggest M&A deal of 2017 — the acquisition of health insurer Aetna by phar...
Impressions : 3842
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.